Abstract
Key Words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyReferences
- CD19 chimeric antigen receptor T cell therapy for haematological malignancies.Br J Haematol. 2015 May; 169: 463-478
- Artificial T-cell receptors.Cytotherapy. 2003; 5: 211-226
- Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med. 2014 Oct 16; 371: 1507-1517
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med. 2018; 378 (01): 439-448
- CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.J Clin Invest. 2016; 126 (01): 2123-2138
- CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.Sci Transl Med. 2013 Mar 20; 5 (177ra38)
- Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.J Clin Oncol. 2015 Feb 20; 33: 540-549
- The growing world of CAR T cell trials: a systematic review.Cancer Immunol Immunother CII. 2016 Dec; 65: 1433-1450
- A guide to manufacturing CAR T cell therapies.Curr Opin Biotechnol. 2018 Feb 17; 53: 164-181
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.Blood. 2016 29; 128: 1688-1700
- Bluebird's BCMA CAR-T impresses at ASH.Nat Biotechnol. 2018 Jan 10; 36: 11
- An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.Blood. 2018 Feb 15; 131: 746-758
- Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.J Clin Invest. 2017 Sep 1; 127: 3462-3471
- Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.Nat Med. 2017 Dec; 23: 1416-1423
- CAR T Cell Therapy for Glioblastoma: Recent Clinical Advances and Future Challenges.Neuro-Oncol. 2018; 20: 1429-1438https://doi.org/10.1093/neuonc/noy032
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.Cancer Immunol Res. 2017 Dec; 5: 1152-1161
- (Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells (Text with EEA relevance) [Internet]. 038, 32006L0017) ([accessed 28.11.06])
- The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.Br J Haematol. 2017 Jan; 176: 9-15
- CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.Hum Gene Ther. 2018 May; 29: 559-568
- GMP CAR-T cell production.Best Pract Res Clin Haematol. 2018 Jun; 31: 126-134
- Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.Immunol Rev. 2014 Jan; 257: 127-144
- Deciphering the EU clinical trials regulation.Nat Biotechnol. 2016 Mar; 34: 231-233
- EudraLex - Volume 4 - Good Manufacturing Practice (GMP) guidelines - Public Health - European Commission [Internet]. Public Health - European Commission [Internet]. Public Health, 2018 (</health/documents/eudralex/vol-4_en>[accessed 17.06.18])
- European Pharmacopoeia 9th Edition. EDQM, 2018 ([Internet) ([accessed 17.06.18])
- Manufacturing genetically modified T cells for clinical trials.Cancer Gene Ther. 2015 Mar; 22: 67-71
- A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.Hum Gene Ther Methods. 2016; 27: 209-218
- CAR-T Cell Therapies From the Transfusion Medicine Perspective.Transfus Med Rev. 2016; 30: 139-145
- AUtologous lymphapheresis for the production of chimeric antigen receptor T cells.Transfusion (Paris). 2017; 57: 1133-1141
- Donor lymphocyte collections using the spectra Optia MNC version 5.Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2013 Apr; 48: 171
- Unstimulated leukapheresis in patients and donors: comparison of two apheresis systems.Transfusion (Paris). 2014 Jun; 54: 1622-1629
- Towards a commercial process for the manufacture of genetically modified T cells for therapy.Cancer Gene Ther. 2015 Mar; 22: 72-78
- Optimization of leukocyte collection and monocyte isolation for dendritic cell culture.Transfus Med Rev. 2010 Apr; 24: 130-139
- Modulation of blood cell activation by four commonly used anticoagulants.Thromb Haemost. 1997 Apr; 77: 690-696
- Confounding effects of platelets on flow cytometric analysis and cell-sorting experiments using blood-derived cells.Cytom Part J Int Soc Anal Cytol. 2006 Feb; 69: 86-94
- Activation-induced T cell apoptosis by monocytes from stem cell products.Int Immunopharmacol. 2001 Jul; 1: 1307-1319
- Monocytes from mobilized stem cells inhibit T cell function.J Leukoc Biol. 1997 May; 61: 583-591
- Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.Cytotherapy. 2016; 18: 893-901
- Large-scale Ficoll gradient separations using a commercially available, effectively closed, system.Cytotherapy. 2010 May; 12: 418-424
- Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies.J Transl Med. 2014 Sep 17; 12: 241
- Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.J Transl Med. 2017 Mar 16; 15: 59
- Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Sci Transl Med. 2016; 8 (07): 355ra116
- Clinical manufacturing of CAR T cells: foundation of a promising therapy.Mol Ther Oncolytics. 2016; 3: 16015
- Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor.Blood [Internet]. 2014 Dec 6; 124 (311–311) (2014 [accessed 24.06.14])
- Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.Cytotherapy. 2014 May; 16: 619-630
- Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.Immunobiology. 2014 Aug; 219: 583-592
- Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.J Immunother. 2009 Mar; 32: 169-180
- AUtomated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.Cytotherapy. 2016; 18: 1002-1011
- Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.PloS One. 2013; 8: e64138
- Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.Cancer Gene Ther. 2015 Mar; 22: 79-84
- Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor.J Immunother. 2015 Apr; 38: 127-135
- Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.Cancer Gene Ther. 2015 Mar; 22: 85-94
- Construction of stable packaging cell lines for clinical lentiviral vector production.Sci Rep. 2015 Mar 12; 5: 9021
- Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.Sci Transl Med. 2012 May 2; 4 (132ra53)
- Gene Therapy with the Sleeping Beauty Transposon System.Trends Genet TIG. 2017; 33: 852-870
- Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells.Cell. 1997 Nov 14; 91: 501-510
- Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4(+) T Cells.Mol Ther J Am Soc Gene Ther. 2016 Mar; 24: 592-606
- Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.Cytotherapy. 2014 Sep; 16: 1257-1269
- Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.Cytotherapy. 2015 Sep; 17: 1251-1267
- Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.Cancer Res. 2011 May 15; 71: 3516-3527
- Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.Cancer Gene Ther. 2015 Mar; 22: 95-100
- Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies.Blood [Internet]. 2015 Dec 3; 126 (862–862) (2015 [accessed 24.06.18])
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.Blood. 2008 Sep 15; 112: 2261-2271
- Simplified process for the production of anti-CD19-CAR-engineered T cells.Cytotherapy. 2013 Nov; 15: 1406-1415
- Optimizing the production of suspension cells using the G-Rex “M” series.Mol Ther Methods Clin Dev. 2014; 1: 14015
- Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment.J Immunother. 2012 Apr; 35: 283-292
- Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.J Transl Med. 2012 Apr 4; 10: 69
- IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes.Blood. 2009 Jan 29; 113: 1006-1015
- Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.Cytotherapy. 2018 Mar; 20: 394-406
- AUtomated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products.Hum Gene Ther. 2016; 27: 860-869
- AUtomated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.Hum Gene Ther. 2017 Oct; 28: 914-925
- Temperature fluctuations during deep temperature cryopreservation reduce PBMC recovery, viability and T-cell function.Cryobiology. 2013 Oct; 67: 193-200
- Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations.Transfusion (Paris). 2017; 57: 1555-1565
- Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.J Immunother. 2018 Jan; 41: 19-31
- EBMT Chronic Leukaemia Working Party Complications Subcommittee. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres.Bone Marrow Transplant. 2005 Oct; 36: 601-603
- Comparative analysis of engraftment after cryopreservation of peripheral blood stem cell autografts by controlled- versus uncontrolled-rate methods.Bone Marrow Transplant. 1994 Jun; 13: 801-804
- Successful short-term cryopreservation of volume-reduced cord blood units in a cryogenic mechanical freezer: effects on cell recovery, viability, and clonogenic potential.Transfusion (Paris). 2014 Jan; 54: 211-223
- Post-thaw viability of cryopreserved peripheral blood stem cells (PBSC) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes.Br J Haematol. 2016; 174: 942-951
- Hematopoietic stem cell processing and cryopreservation.J Clin Apheresis. 1992; 7: 132-134
- Genetic Modification of T Cells.Biomedicines. 2016 Apr 20; 4
Briefing Document — Testing for Replication Competent Retrovirus (RCR)/Lentivirus (RCL) in Retroviral and Lentiviral Vector Based Gene Therapy Products — Revisiting Current FDA Recommendations:18, 2010.
- Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapy.Cytotherapy. 2018 May; 20: 601-622
- Validation of Analytical Procedures: Text and Methodology : ICH, 2018 ([Internet) ([accessed 17.06.18])
- Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products; Availability. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, January 2011 (2011 - Google Search [Internet]. [accessed 24.06.18])
- Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy.Nat Biotechnol. 2016 Apr; 34: 430-434
- Failures in CAR T-cell products manufacturing.([Internet]) ([accessed 17.06.18])
- Bioengineering Solutions for Manufacturing Challenges in CAR T Cells.Biotechnol J. 2018 Feb; 13